MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress PARIS, France – January 23, 2025 – 10:05 PM ...

William & Mary's Graduate Center invites graduate students conducting research in Humanities, Humanistic Social Sciences, and the Sciences to present at the upcoming Graduate Research Symposium.

You must submit your abstract using the online submission form. Abstracts sent by email will not be considered. Abstracts that are incomplete will not be considered. All ESA Annual Meeting proposal ...

CAMBRIDGE, Mass. & MONTREAL, April 25, 2025--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced ...

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in ...